Treatment with an oral suspension of active gold as an adjunct to disease-modifying therapy was linked to improved neurological function in those with stable relapsing MS, according to a poster presented at ECTRIMS 2023.
“CNM-Au8, an oral suspension of catalytically active gold nanocrystals, supports brain energy metabolism resulting in neuroprotection and remyelination in preclinical models,” Heidi Beadnall, MBBS, FRACP, researcher at Clene Nanomedicine Inc., and colleagues wrote.
In the phase 2 multicenter, randomized, double-blind, placebo-controlled VISIONARY-MS clinical trial,